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(29%) developed a thrombotic thrombocytopenic 
purpuraAnicroangiopathic hemolytic anemia syndrome or an 
acute hemolytic reaction that was treated with plasmapheresis or 
red cell exchange. Twenty-one of 30 (70%) evaluable patients 
developed grade II-IV acute GVHD. Of these, 62% had grade 
III-IV acute GVItD. Sixteen of 21 (76%) evaluable patients, 
developed chronic GVHD with 63% of those patients having 
extensive chronic GVHD. The day 100 survival was 68%. Ten 
patients are alive at a median of 67.6 months (range: 45.2-82.3), 
for an overall survival of 32%. These results indicate that, in con- 
trast to its effects after allogeneic BMT, single-agent tacrolimus 
does not adequately prevent GVHD after related allogeneic 
PBSCT. 
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PHASE II STUDY OF DENILEUKIN DIFTITOX (ONTAK) IN THE 
TREATEHENT OF STEROID RESISTANT ACUTE GRAFT VERSUS HOST 
DISEASE (AGVHD) 
Shat~g',~nes~, P.; Bachier, C.; G'dmley, M.; LeMaid'tre, C.F. Texas 
Transplant lnstitute, San Anto~lio, TX. 
AGVHD is one of the pricipal complications of allogeneic 
heluatopoietic stem cell transplantation. Ontak is a recombi- 
nant DNA derived cytotoxic fusion protein designed to direct 
the cytocidal action of diphtheria toxin to cells with high affin- 
ity of the IL-2 receptor. We designed a phase II trial to exam- 
ine the Ontak in patients (pts) with steroid resistant AGVHD. 
Steroid resistance was defined as treatment with 2mg/kg of 
methylprednisolone and progressive disease after 3 days or sta- 
ble disease after 7 days. Ontak treatment was 4.Smcg/kg/day 
IV for 5 days followed by the same dose weekly for 4 weeks. 
Four pts have been treated to date. Pt #I had stage 3 skin and 
stage 4 GI AGVHD that improved to stage 1 skin and stage 1 
GI by day 5 of the Ontak. Ontak was held in this pt because of 
a low albumin and fluid retention. GVHD recurred 4 weeks 
after Ontak was held and, despite treatment with inflixamab, 
GVHD progressed and the pt died of psuedonmnas sepsis. Pt 
#2 had stage 3 skin AGVHD that responded completely by day 
5 of the Ontak and finished 3 of the 4 weekly treatments, with 
the last treatment held for pancytopenia. Pt #3 had stage 4 GI 
and conjuctival AGVHD that completely resolved by day 5 of 
Ontak and finished all treatments. Pt #4 had stage 4 liver, 3 
skin, and 4 GI AGVHD that progressed after the first 5 day 
infusion of Ontak and was taken off study and treated with 
inflixilnab with an improvement to stage 3 liver, 0 skin, and 4 
GI AGVHD. Pt #4 had a generalized tonic-clonic seizure on 
day 2 of the Ontak infusion that was felt to be related to 
cyclosporine and completed the Ontak infusion with no fur 
ther neurologic sequalae. Pt #4 also developed isseminated 
adeuovirus. Pts #2 and #3 had grade III hematologic toxicity 
that was felt to be multifactorial and both also had bacterial 
upper respiratory tract infections that were treated and 
resolved. Patient #3 had CMV reactivation that was pre-emp- 
tively treated with valgancyclovir and resolved. Pts #2 and #3 
are both greater than 100 days from the start of the Ontak 
treatment and have been tapered to less than 0.5mg/kg or 
steroids while remaining on FK506 with no evidence of 
AGVHD. In conclusion, the low dose of Ontak used in this 
study appears active in AGVHD with acceptable toxicity. Fur- 
ther study to assess infection risk, response rates, and patient 
survival are warranted. .... 
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SELECTIVE DEPLETION OF HUMAN GVH-REACTIVE T-CELLS BY 
ANTI-CD95 MEDIATED ACTIVATION-INDUCED CELL DEATH OR VIA 
THE T-CELL ACTIVATION ANTIGEN CD69 FOR PREVENTING GRAFT- 
VERSUS-HOST DISEASE IN ALLO-BMT 
Norm, M.; Tnbbe, i.; Hnber, C.; Hartwig, U.F. Dept. of Hematology, 
Mamz, GelwzaJTy. 
Depletion of T-cells from allogeneic bone marrow transplants 
(BMT) ameliorates GvHD but is associated with impaired 
engraftment, inmmnosuppression, a dabrogation of the benefi- 
cial graft-versus-leukemia effect (GvL). We, therefore, explored 
the possibility of separating alloreactivity from T lymphocytes 
mediating GvL-responses x vivo by selective depletion of GvH- 
reactive T-cells using CD95/CD178-mediated activation induced 
cell death (MCD) or via the T-cell activation antigen CD69. T- 
cells purified from human PBMC were stinmlated with fully-mis 
matched stimulators in an allogeneic mixed lymphocyte culture 
(MLC) in the presence of agonistic anti-CD95 mAb. Specificity of 
depletion was tested by consecutively monitoring CMV-pp65 spe- 
cific T-cells present in PBMC from seropositive donors before 
and after MCD. As reported earlier in a murine model, prolifera- 
tive responses ofalloreactive T-cells were reduced 65-90% in the 
presence of anti-CD95 reagents depending on the mAb used. 
ELISpot analysis revealed the retainment ofpp65-specific T-cells 
in the residual allogeneic T-lymphocyte population comparable to 
frequencies detected in normal controls. In comparative studies, 
elimination of alloreactive specificities by imnmnomagnetic sepa- 
ration using the T-cell activation marker CD69 resulted in 3 sub- 
sets ofT-cells. Restimulation ofCD69- cells (> 98%) as well as the 
CD69 + population and the CD69 dull cells retrieved from the wash- 
fraction with 1st party stimulators esulted in a substantial reduced 
proliferation of the CD69- cells as compared to he positive sub- 
set. The CD69 d~ll T-lymphocytes also showed residual alloreactiv- 
ity. Interestingly, monitoring for pp65-reactive T-cells by 
ELISpot analysis indicated that the majority of pp65-specific T- 
cells appeared to be enriched in the CD69 '1"11 population. Further 
studies on the efficacy, specificity and potential of retained allo- 
geneic T-cells to respond to l~mwn leukemia associated antigens 
in HLA-naislnatched as well as HLA-lnatched settings are in 
progress and will be discussed. 
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SERUM CYTOKINE PROFILES OF PATIENTS WITH ACUTE GVHD 
TREATED WITH METHYLPREDNISOLONE ALONE OR IN COMBINA- 
TION WITH INFLIXIMAB ARE DIFFERENT 
Lee, B.; Couvie/, D.; Shen, D.; Hhlze, L.; C,Oam, plin, R.; Re~tt, e~7, J.M. 
M.D.Anderson Uancer Center, Houston, TX. 
Graft-versus-host disease (GVHD) is a major problem for recip- 
ients of allogeneic blood and marrow transplantation. GVHD, 
mediated by TNF-alpha produced by activated mononuclear cells, 
can be treated with methylprednisolone (NIP) or in combination 
with Infli.'dmab (I), a chimeric human/lnouse anti-TNF antibody 
that interferes with the activity of TNF-alpha. Moreover, as acute 
GVHD (aGVHD) is linked to increases in the levels of inflamma- 
tory cytokines, we hypothesized that there would be a decrease in
inflammatory cytokines as patients achieved a complete response 
following treatment for aGVHD. Therefore, we collected sera 
from 52 patients with aGVHD who were randomized to one of 
two treatment arms to receive either methylprednisolone (MP) or 
MP plus Infli~mab (MP+I) once a week for 4 weeks. We meas- 
ured serum levels of IL-2, IL-6, IL-10, IL-12, TNF-alpha, and 
IFN-gamma pre-treatment and at weekly intervals thereafter for 5 
weeks on a subset of patients with aGVHD. We analyzed CTtokine 
data for 10 MP and 10 MP+I patients. The levels of IL-6, IL-10, 
, IL-12, and IFN-gamma before and after treatment were similar 
for both groups. The profiles of IL 2 and TNF2alpha levels over 
time however were different for the 2 groups. The levels of these 
cytokines in the MP+I group peaked in the first wo weeks of 
treatment and declined thereafter. Conversely, the levels of IL-2 
and TNF-alpha in the MP group were low in the first two weeks 
of treatment and increased thereafter. These preliminal T data sug- 
gest that there may be differences in the profiles of IL-2 and 
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